TY - JOUR AB - Following the publication of the above article, the authors have realized that the same image had been selected to show H&E staining of the ovarian slices in the Control and 10 μM groups in Fig. 4A. After reviewing the original pictures, the authors discovered that the image correctly showing the data for the 48 h, 10 μM group had also been used for the 48 h Control group. The corrected version of Fig. 4, showing the correct data for the 48 h Control group in Fig. 4A, is shown below. It should be noted that the inadvertent error that occurred during the compilation of this figure did not affect the results or the conclusions of this article. The authors all agree to this Corrigendum, and are grateful to the Editor of Oncology Reports for granting them the opportunity to correct this figure. The authors also apologize to the readership for any inconvenience caused. [the original article was published in Oncology Reports 44: 1127‑1135, 2020; DOI: 10.3892/or.2020.7660] AD - Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China AU - Liao,Qiuyue AU - Feng,Xue AU - Li,Xi AU - Chen,Ge AU - Chen,Jing AU - Yang,Bin AU - Li,Kezhen AU - Ai,Jihui DA - 2021/07/01 DO - 10.3892/or.2021.8074 IS - 1 JO - Oncol Rep KW - lapatinib ovarian reserve reproductive function EGF receptor STAT3 signaling pathway PY - 2021 SN - 1021-335X 1791-2431 SP - 123 ST - [Corrigendum] Lapatinib‑induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro T2 - Oncology Reports TI - [Corrigendum] Lapatinib‑induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro UR - https://doi.org/10.3892/or.2021.8074 VL - 46 ER -